NEW YORK (GenomeWeb News) – A US federal district court has denied Myriad Genetics and other patent holders' request for a preliminary injunction against competitor Ambry Genetics to stop it from performing and selling tests that gauge BRCA genetic mutations.
In the wake of the US Supreme Court's decision to strike down Myriad Genetics' patents on isolated BRCA1 and BRCA2 gene sequences, GeneDx this week become the latest laboratory to launch sequencing-based tests for inherited cancer that include those genes.
After being sued by Myriad Genetics for allegedly infringing its patents on BRCA1 and BRCA2 gene mutation testing, Ambry Genetics pushed back this week with its own countersuit accusing Myriad of antitrust violations.
NEW YORK (GenomeWeb News) – In response to Myriad Genetics' patent infringement lawsuit against Ambry Genetics, the Aliso Viejo, Calif.-based testing firm took its own legal action today by countersuing Myriad for antitrust violations.
Ever since the Supreme Court struck down Myriad Genetics' patent claims on isolated BRCA1 and BRCA2 gene sequences, industry observers have breathlessly speculated whether the company would take legal action against labs challenging its decades-long reign over the BRCA genetic te
Ardy Arianpour is now senior vice president of business development at Ambry Genetics. He previously served as vice president of business development at the company. Arianpour joined Ambry in 2009 after holding several positions at Cogenics.